For the quarter ending 2025-09-30, EKSO had -$2,520K decrease in cash & cash equivalents over the period. -$2,073K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,421 | -5,600 |
| Depreciation and amortization | 367 | 755 |
| Loss on impairment of intangible asset | 0 | 180 |
| Changes in provision for credit losses on accounts receivable | -13 | 5 |
| Gain on revaluation of warrant liabilities | 0 | 1 |
| Stock-based compensation expense | 234 | 457 |
| Loss on modification of warrant | 0 | 0 |
| Common stock contribution to 401 plan | 64 | 15 |
| Unrealized gain on foreign currency transactions | 4 | 1,965 |
| Accounts receivable | 1,507 | -3,052 |
| Inventories | -494 | 881 |
| Prepaid expenses and other assets, current and noncurrent | 283 | 164 |
| Accounts payable | 216 | -121 |
| Accrued, lease and other liabilities, current and noncurrent | -38 | -716 |
| Deferred revenues | -170 | -425 |
| Net cash used in operating activities | -2,061 | -5,409 |
| Acquisition of property and equipment | 12 | 50 |
| Net cash used in investing activities | -12 | -50 |
| Principal payments under notes payable | 313 | 625 |
| Retirement of term loan-Term Loan | 2,000 | - |
| Proceeds from issuance of common stock, net | -48 | 914 |
| Proceeds from exercise of warrants, net | 0 | 3,856 |
| Proceeds from issuance of convertible promissory note, net-Promissory Note | 1,924 | - |
| Net cash provided by financing activities | -437 | 4,145 |
| Effect of exchange rate changes on cash | -10 | 63 |
| Net decrease in cash | -2,520 | -1,251 |
| Cash and cash equivalents at beginning of period | 6,493 | - |
| Cash and cash equivalents at end of period | 2,722 | - |
EKSO BIONICS HOLDINGS, INC. (EKSO)
EKSO BIONICS HOLDINGS, INC. (EKSO)